Tempus ECG-AF vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Tempus ECG-AF

by Tempus AI, Inc.

ElucidVivo A.3

by Elucid

AI Verdict

Tool A (Tempus ECG-AF) focuses on predicting the risk of atrial fibrillation using ECG data, aiding in early identification for patients aged 65 or older. Tool B (ElucidVivo A.3), conversely, analyzes CT angiography to quantify arterial plaque composition and stability, assisting in atherosclerosis patient stratification. While both are cardiology AI tools, they address distinct cardiovascular conditions and utilize different diagnostic inputs, making them adjacent rather than direct competitors.

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if you need to proactively identify elderly patients at increased risk of developing new-onset atrial fibrillation within the next 12 months. This tool is ideal for screening patients aged 65 or older without a prior AF diagnosis, leveraging standard 12-lead ECGs to support earlier intervention and follow-up for this common arrhythmia.

View Tempus ECG-AF →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require in-depth quantitative analysis of arterial plaque composition and stability from CT angiography images. This system is best suited for stratifying patients with existing atherosclerosis, providing critical insights into plaque vulnerability (e.g., LRNC quantification) to optimize treatment decisions and visualize vessel pathology in 3D.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Tempus ECG-AF	ElucidVivo A.3
Pricing	Contact vendor	Unknown
Deployment	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.	Cloud and on-premise secure deployment.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Yes AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tempus ECG-AF

Tempus ECG-AF integrates directly into existing healthcare facility systems and is compatible with standard FDA-authorized 12-lead ECG devices, operating without a dedicated user interface. This approach minimizes workflow disruption and the need for clinicians to learn a new system, making it highly usable within established cardiology workflows.

Clinical Value

ElucidVivo A.3

While both tools are FDA-cleared and address critical cardiovascular needs, ElucidVivo A.3 offers a more profound and predictive clinical insight by providing quantitative analysis of arterial plaque composition and stability from CT angiography, validated against histology. Its ability to objectively quantify specific plaque components and derive fractional flow reserve (FFRct) offers a deeper level of detail for atherosclerosis patient stratification and treatment optimization.

Pricing & Value

Tempus ECG-AF

Tempus ECG-AF has a significant advantage due to the explicit mention of established CMS reimbursement (CPT 0764T and CPT 0765T with a Medicare rate of $128.90, effective January 1, 2025). This clear reimbursement pathway substantially de-risks adoption and provides a tangible financial value proposition for healthcare providers, which is not detailed for ElucidVivo A.3.

Enterprise Readiness

Tempus ECG-AF

Tempus ECG-AF explicitly states that it is HIPAA compliant and offers a Business Associate Agreement (BAA), which are fundamental requirements for enterprise adoption in healthcare. ElucidVivo A.3 implies these aspects due to its FDA clearance and intended use, but does not explicitly state them in the provided information, making Tool A more transparent and ready for enterprise deployment.

Innovation

ElucidVivo A.3

Both tools are innovative applications of AI in cardiology. However, ElucidVivo A.3 demonstrates greater innovation by offering quantitative analysis of arterial plaque composition and stability from CT angiography, validated against ground-truth histology, and deriving fractional flow reserve (FFRct). This provides highly detailed and predictive insights for personalized atherosclerosis management, pushing beyond traditional diagnostic assistance.

Support & Docs

Tempus ECG-AF

Tempus ECG-AF provides clear support channels, including a dedicated 'Tempus Cardiology Support team' with an email address and phone number, and a 'Document Library' on their website for technical information. In contrast, specific support contacts or a dedicated documentation portal for ElucidVivo A.3 are not explicitly detailed in the available information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Tempus ECG-AF	ElucidVivo A.3
Tool Name	Tempus ECG-AF	ElucidVivo A.3
Company	Tempus AI, Inc.	Elucid Bioimaging
Description	FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up.	FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography. It assists physicians in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed visualization and measurement of plaque characteristics validated against histology.
Target Patient Population/Use Case	Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, to detect signs associated with new onset Atrial Fibrillation (AF) within 12 months.	Aids in stratifying patients with atherosclerosis and optimizing treatment decisions by analyzing arterial plaque composition and stability from CT angiography.
Input Data Type	12-lead ECG recordings (compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems).	CT angiography images.
Key Output/Analysis	Identifies patients at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.	Quantitative analysis of Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images; visualization of lesion-level plaque composition; 3D visualization of highlighted vessels; rotatable curved MPR vessel views and cross-sections; derives fractional flow reserve (FFRct).

Videos

Demos, reviews, and walkthroughs featuring Tempus ECG-AF and ElucidVivo A.3.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and what are the typical data input requirements for each?

Tempus ECG-AF is a software solution integrated into healthcare facility systems and is compatible with FDA-authorized 12-lead ECGs from GE Medical Systems and Philips Medical Systems, requiring standard ECG recordings as input. ElucidVivo A.3 integrates with PACS/EMR systems, utilizing CT angiography images for its quantitative plaque analysis.

What specific clinical insights do these tools provide, and for which patient populations are they most relevant?

Tempus ECG-AF identifies patients aged 65 or older at increased risk of developing new-onset atrial fibrillation/flutter (AF) within 12 months, excluding those with pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. ElucidVivo A.3 provides quantitative analysis of arterial plaque composition and stability from CT angiography to stratify atherosclerosis patients and optimize treatment decisions, including deriving fractional flow reserve (FFRct).

What are the underlying validation methods and datasets that support the accuracy and reliability of each tool's analytical results?

Tempus ECG-AF was trained on over 1.5 million ECGs from over 500,000 patients and underwent clinical performance validation in a retrospective observational study of 4,017 patients. ElucidVivo A.3's quantitative plaque analysis and FFRct derivation are validated against ground-truth histology, providing objective measurements of plaque characteristics.

What is the expected learning curve for physicians and clinical staff to become proficient with each tool, and how quickly can a practice realize its benefits?

Both tools are software solutions designed for integration into existing systems, suggesting a moderate learning curve for interpretation and workflow adaptation. Time-to-value will depend on the specific clinical setting, the efficiency of integration into existing diagnostic pathways, and the training provided by the vendor.

Do these tools offer robust audit-trail features to track the use of AI-generated insights and support clinical decision-making documentation?

While not explicitly detailed in the provided information, as medical software, both tools would typically include logging capabilities for data processing and result generation. The specific depth of audit-trail features for physician interaction with AI insights and documentation support would need to be confirmed with each vendor.

What are the practical considerations for implementing and scaling each tool across multiple clinical sites or a large healthcare system?

For Tempus ECG-AF, key considerations include compatibility with existing GE and Philips ECG machines and seamless integration into facility systems and EHRs. ElucidVivo A.3's integration with PACS/EMR systems would be central to a multi-site rollout, requiring coordination with imaging and IT infrastructure.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Tempus ECG-AF or ElucidVivo A.3

Backers

Who funded each tool's parent company.